# Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer

> **NCT00374322** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 3166 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** lapatinib
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00374322
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2011-09
- **Final completion:** 2013-07
- **Target enrollment:** 3166 (ACTUAL)
- **Last updated:** 2014-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00374322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00374322, "Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00374322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*